What question did this study set out to answer?

To compare the efficacy and safety of immediate multivessel PCI versus staged multivessel PCI in hemodynamically stable patients presenting with STEMI and multivessel coronary artery disease.

August 27, 2023ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)183 citationsOpen Access

Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction

BSBarbara E. Stähli FVFerdinando Varbella ALAxel Linke

Key Points

To compare the efficacy and safety of immediate multivessel PCI versus staged multivessel PCI in hemodynamically stable patients presenting with STEMI and multivessel coronary artery disease.
Randomized noninferiority clinical trial (MULTISTARS AMI, NCT03135275) evaluating hemodynamically stable patients with STEMI and multivessel coronary artery disease.
Patients underwent either immediate multivessel PCI or staged multivessel PCI.
Follow-up assessed a composite endpoint of all-cause mortality, nonfatal myocardial infarction, stroke, unplanned ischemia-driven revascularization, or heart failure hospitalization at 1 year.
Immediate multivessel PCI met noninferiority criteria relative to staged multivessel PCI for the primary composite endpoint at 1 year (detailed event rates, hazard ratios, 95% CIs, and p-values not reported in the abstract).

Abstract

Among patients in hemodynamically stable condition with STEMI and multivessel coronary artery disease, immediate multivessel PCI was noninferior to staged multivessel PCI with respect to the risk of death from any cause, nonfatal myocardial infarction, stroke, unplanned ischemia-driven revascularization, or hospitalization for heart failure at 1 year. (Supported by Boston Scientific; MULTISTARS AMI ClinicalTrials.gov number, NCT03135275.).

Expert Takes1 quote

“The key message of the MULTISTARS-AMI trial is that we could show that in patients with STEMI and multivessel disease, immediate multivessel PCI is noninferior to staged multi-vessel PCI based on the 1-year risk for the composite of all cause death, non-fatal myocardial infarction, stroke, unplan...”

Medscape CardiologyView source

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Stähli et al. (2023) studied this question.

synapsesocial.com/papers/69dbe6a8eb8801008ea3c2cd https://doi.org/10.1056/nejmoa2307823

Ask AI

Helpful

Bookmark

View Full Paper

August 27, 2023ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)183 citationsOpen Access

Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction

BSBarbara E. Stähli FVFerdinando Varbella ALAxel Linke

Key Points

To compare the efficacy and safety of immediate multivessel PCI versus staged multivessel PCI in hemodynamically stable patients presenting with STEMI and multivessel coronary artery disease.
Randomized noninferiority clinical trial (MULTISTARS AMI, NCT03135275) evaluating hemodynamically stable patients with STEMI and multivessel coronary artery disease.
Patients underwent either immediate multivessel PCI or staged multivessel PCI.
Follow-up assessed a composite endpoint of all-cause mortality, nonfatal myocardial infarction, stroke, unplanned ischemia-driven revascularization, or heart failure hospitalization at 1 year.
Immediate multivessel PCI met noninferiority criteria relative to staged multivessel PCI for the primary composite endpoint at 1 year (detailed event rates, hazard ratios, 95% CIs, and p-values not reported in the abstract).

Abstract

Expert Takes1 quote

Medscape CardiologyView source

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Stähli et al. (2023) studied this question.

synapsesocial.com/papers/69dbe6a8eb8801008ea3c2cd https://doi.org/10.1056/nejmoa2307823

Ask AI

Helpful

Bookmark

View Full Paper